1492 Capital Management’s Axsome Therapeutics AXSM Stock Holding History

1492 Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.14M	Buy	18,594 +531	+3%	+$91.7K	1.2%	33
2025 Q4	$3.3M	Hold	18,063	–	–	1.26%	34
2025 Q3	$2.19M	Buy	18,063 +6,220	+53%	+$701K	0.89%	46
2025 Q2	$1.24M	Buy	+11,843	New	+$1.25M	0.57%	63
2025 Q1	–	Sell	-11,385	Closed	-$963K	–	116
2024 Q4	$963K	Buy	+11,385	New	+$1.05M	0.46%	60

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

1492 Capital Management's AXSM Position: Q1 2026 in Review

1492 Capital Management increased its Axsome Therapeutics (AXSM) stake by 2.9% in Q1 2026, buying an estimated $91.7K and bringing the position to 18,594 shares worth $3.14M. The position accounts for 1.2% of the portfolio, ranked #33.

1492 Capital Management first reported a position in AXSM in Q4 2024 and has held it in 5 quarters since. The position peaked at $3.3M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

1492 Capital Management held 18,594 shares of Axsome Therapeutics worth $3.14M as of Q1 2026.
1492 Capital Management bought 531 Axsome Therapeutics shares in Q1 2026, an estimated $91.7K.
Axsome Therapeutics made up 1.2% of 1492 Capital Management's portfolio in Q1 2026, its #33 holding.
1492 Capital Management first reported a position in Axsome Therapeutics in Q4 2024 and has held it in 5 quarters since.
1492 Capital Management's Axsome Therapeutics position peaked at $3.3M in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on 1492 Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.